Apolipoprotein A1 and C-terminal fragment of α-1 antichymotrypsin are candidate plasma biomarkers associated with acute renal allograft rejection

Transplantation

Volumn 92, Issue 4, 2011, Pages 388-395

  Ziegler, Mary E ^a   Chen, Tingchao ^a   Leblanc, James F ^a   Wei, Xuelian ^a   Gjertson, David W ^a   Li, Ker Chau ^a   Khalighi, Mazdak A ^a   Lassman, Charles R ^a   Veale, Jeffrey L ^b   Gritsch, H Albin ^b   Reed, Elaine F ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Acute cellular rejection; Biomarker; Proteomics; Renal; Transplantation

Indexed keywords

ALPHA 1 ANTICHYMOTRYPSIN; ALPHA 1 ANTICHYMOTRYPSIN CARBOXYL TERMINAL FRAGMENT; APOLIPOPROTEIN A1; UNCLASSIFIED DRUG;

ACUTE GRAFT REJECTION; ADULT; ARTICLE; CASE CONTROL STUDY; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE MARKER; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; KIDNEY ALLOGRAFT REJECTION; KIDNEY BIOPSY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; QUANTITATIVE ASSAY; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY;

ACUTE DISEASE; ADULT; ALPHA 1-ANTICHYMOTRYPSIN; APOLIPOPROTEIN A-I; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; COHORT STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GRAFT REJECTION; HUMANS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; PROTEIN ARRAY ANALYSIS; SENSITIVITY AND SPECIFICITY; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 80051783611     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e318225db6a     Document Type: Article

References (37)

1. Li B, Hartono C, Ding R, et al. Noninvasive diagnosis of renal-allograft rejection by measurement of messenger RNA for perforin and granzyme B in urine. N Engl J Med 2001;344:947.
2. Clarke W. Proteomic research in renal transplantation. Ther Drug Monit 2006;28:19.
3. Beckingham IJ, Nicholson ML, Bell PR. Analysis of factors associated with complications following renal transplant needle core biopsy. Br J Urol 1994;73:13.
4. Rush DN, Henry SF, Jeffery JR, et al. Histological findings in early routine biopsies of stable renal allograft recipients. Transplantation 1994;57:208.
5. Hu S, Loo JA, Wong DT. Human body fluid proteome analysis. Proteomics 2006;6:6326.
6. Lescuyer P, Hochstrasser D, Rabilloud T. How shall we use the proteomics toolbox for biomarker discovery? J Proteome Res 2007;6:3371.
7. Reddy G, Dalmasso EA. SELDI ProteinChip (R) array technology: Protein-based predictive medicine and drug discovery applications. J Biomed Biotechnol 2003;2003:237.
8. Albitar M, Potts SJ, Giles FJ, et al. Proteomic-based prediction of clinical behavior in adult acute lymphoblastic leukemia. Cancer 2006;106:1587.
9. Clarke W, Silverman BC, Zhang Z, et al. Characterization of renal allograft rejection by urinary proteomic analysis. Ann Surg 237:660-4, 2003; discussion 664.
10. Schaub S, Wilkins J, Weiler T, et al. Urine protein profiling with surface-enhanced laser-desorption/ionization time-of-flight mass spectrometry. Kidney Int 2004;65:323.
11. O'Riordan E, Orlova TN, Mei JJ, et al. Bioinformatic analysis of the urine proteome of acute allograft rejection. J Am Soc Nephrol 2004;15:3240.
12. Voshol H, Brendlen N, Muller D, et al. Evaluation of biomarker discovery approaches to detect protein biomarkers of acute renal allograft rejection. J Proteome Res 2005;4:1192.
13. Jahnukainen T, Malehorn D, Sun M, et al. Proteomic analysis of urine in kidney transplant patients with BK virus nephropathy. J Am Soc Nephrol 2006;17:3248.
14. O'Riordan E, Orlova TN, Podust VN, et al. Characterization of urinary peptide biomarkers of acute rejection in renal allografts. Am J Transplant 2007;7:930.
15. Ling XB, Sigdel TK, Lau K, et al. Integrative urinary peptidomics in renal transplantation identifies biomarkers for acute rejection. J Am Soc Nephrol 2010;21:646.
16. Freue GV, Sasaki M, Meredith A, et al. Proteomic signatures in plasma during early acute renal allograft rejection. Mol Cell Proteomics 2010;9:1954.
17. Pimenta DC, Chen VC, Chao J, et al. Alpha1-antichym ot rypsin and kallistatin hydrolysis by human cathepsin D. J Protein Chem 2000;19:411.
18. Lenarcic B, Krasovec M, Ritonja A, et al. Inactivation ofhuman cystatin C and kininogen by human cathepsin D. FEBS Lett 1991;280:211.
19. Zhang S, Janciauskiene S. Multi-functional capability of proteins: Alpha1-antichymotrypsin and the correlation with Alzheimer's disease. J Alzheimers Dis 2002;4:115.
20. Gibson TL, Cohen P. Inflammation-related neutrophil proteases, cathepsin G and elastase, function as insulin-like growth factor binding protein proteases. Growth Horm IGF Res 1999;9:241.
21. Koo DD, Welsh KI, Roake JA, et al. Ischemia/reperfusion injury in human kidney transplantation: An immunohistochemical analysis of changes after reperfusion. Am J Pathol 1998;153:557.
22. Navab M, Anantharamaiah GM, Hama S, et al. Oral administration of an Apo A-I mimetic Peptide synthesized from D-amino acids dramatically reduces atherosclerosis in mice independent of plasma cholesterol. Circulation 2002;105:290.
23. Navab M, Anantharamaiah GM, Reddy ST, et al. Apolipoprotein A-I mimetic peptides. Arterioscler Thromb Vasc Biol 2005;25:1325.
24. Hsieh GR, Schnickel GT, Garcia C, Shefizadeh A, Fishbein MC, Ardehali A. Inflammation/oxidation in chronic rejection: Apolipoprotein a-i mimetic peptide reduces chronic rejection of transplanted hearts. Transplantation 2007;84:238.
25. Yuditskaya S, Tumblin A, Hoehn GT, et al. Proteomic identification of altered apolipoprotein patterns in pulmonary hypertension and vasculopathy of sickle cell disease. Blood 2008;113:1122.
26. Engwegen JY, Helgason HH, Cats A, et al. Identification of serum proteins discriminating colorectal cancer patients and healthy controls using surface-enhanced laser desorption ionisation-time of flight mass spectrometry. World J Gastroenterol 2006;12:1536.
27. Kozak KR, Su F, Whitelegge JP, et al. Characterization of serum biomarkers for detection of early stage ovarian cancer. Proteomics 2005;5:4589.
28. Ndao M, Spithill TW, Caffrey R, et al. Identification ofnovel diagnostic serum biomarkers for Chagas' disease in asymptomatic subjects by mass spectrometric profiling. J Clin Microbiol 2010;48:1139.
29. Choi DH, Lee WS, Won M, et al. The apolipoprotein A-I level is downregulated in the granulosa cells of patients with polycystic ovary syndrome and affects steroidogenesis. J Proteome Res 2010;9:4329.
30. Nicholas BL, Skipp P, Barton S, et al. Identification of lipocalin and apolipoprotein A1 as biomarkers of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2010;181:1049.
31. Burger D, Dayer JM. High-density lipoprotein-associated apolipoprotein A-I: The missing link between infection and chronic inflammation? Autoimmun Rev 2002;1:111.
32. Fishman JA, Rubin RH. Infection in organ-transplant recipients. N Engl J Med 1998;338:1741.
33. Shevchenko A, Chernushevich I, Wilm M, et al. De Novo peptide sequencing by nanoelectrospray tandem mass spectrometry using triple quadrupole and quadrupole/time-of-flight instruments. Methods Mol Biol 2000;146:1.
34. Shevchenko A, Chernushevich I, Ens W, et al. Rapid 'de novo' peptide sequencing by a combination of nanoelectrospray, isotopic labeling and a quadrupole/time-of-flight mass spectrometer. Rapid Commun Mass Spectrom 1997;11:1015.
35. Racusen LC, Colvin RB, Solez K, et al. Antibody-mediated rejection criteria-An addition to the Banff 97 classification of renal allograft rejection. Am J Transplant 2003;3:708.
36. Racusen LC, Solez K, Colvin RB, et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999;55:713.
37. Albrethsen J. Reproducibility in protein profiling by MALDI-TOF mass spectrometry. Clin Chem 2007;53:852.